Combined use of brain natriuretic peptide and C-reactive protein for predicting cardiovascular risk in outpatients with type 2 diabetes mellitus

Vascular Health and Risk Management

Volumn 3, Issue 4, 2007, Pages 417-423

  Tsuruda, Toshihiro ^a   Kato, Johji ^a   Sumi, Takahiro ^a   Mishima, Kazuya ^a   Masuyama, Hiroyuki ^a   Nakao, Hiroyuki ^b   Imamura, Takuroh ^a   Eto, Tanenao ^a   Kitamura, Kazuo ^a  

^a UNIVERSITY OF MIYAZAKI   (Japan)

^b UNIVERSITY OF MIYAZAKI   (Japan)

Author keywords

Diabetes mellitus; Inflammation; Mortality and morbidity; Natriuretic peptide

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIGUANIDE; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLINIDE; GLITAZONE DERIVATIVE; GLYCOSIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SULFONYLUREA; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIAGNOSTIC VALUE; ELECTROCARDIOGRAM; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTPATIENT; PREDICTION; PROGNOSIS; PROTEIN BLOOD LEVEL; RECURRENT DISEASE; RISK ASSESSMENT; RISK FACTOR; URINALYSIS;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; OUTPATIENTS; PROGNOSIS; RISK ASSESSMENT; ULTRASONOGRAPHY, DOPPLER, COLOR;

EID: 35148843779     PISSN: 11766344     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. [ADA] American Diabetes Association, The National Heart, Lung, and Blood Institute, the juvenile diabetes foundation international, et al. 1999. Diabetes mellitus: a major risk factor for cardiovascular disease. A joint editorial statement by the american diabetes association; The national heart, lung, and blood institute; The juvenile diabetes foundation international; The national institute of diabetes and digestive and kidney diseases; and The american heart association. Circulation, 100:1132-3.
2. Booth GL, Kapral MK, Fung K, et al. 2006. Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: a population-based retrospective cohort study. Lancet, 368:29-36.
3. Danesh J, Wheeler JG, Hirschfield GM, et al. 2004. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med, 350:1387-97.
4. Dawson A, Jeyaseelan S, Morris AD, et al. 2005. B-type natriuretic peptide as an alternative way of assessing total cardiovascular risk in patients with diabetes mellitus. Am J Cardiol, 96:933-4.
5. de Lemos JA, Morrow DA, Bentley JH, et al. 2001. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med, 345:1014-21.
6. Devereux RB, Alonso DR, Lutas EM, et al. 1986. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol, 57:450-8.
7. Epshteyn V, Morrison K, Krishnaswamy P, et al. 2003. Utility of B-type natriuretic peptide as a screen for left ventricular dysfunction in patients with diabetes. Diabetes Care, 26:2081-7.
8. Fang ZY, Schull-Meade R, Leano R, et al. 2005. Screening for heart disease in diabetic subjects. Am Heart J, 149:349-54.
9. Garcia MJ, McNamara PM, Gordon T, et al. 1974. Morbidity and mortality in diabetics in the Framingham population. Sixteen year follow-up study. Diabetes, 23:105-11.
10. Howard BV, Best LG, Galloway JM, et al. 2006. Coronary heart disease risk equivalence in diabetes depends on concomitant risk factors. Diabetes Care, 29:391-7.
11. Ishikawa C, Tsutamoto T, Fujii M, et al. 2006. Prediction of mortality by high-sensitivity C-reactive protein and brain natriuretic peptide in patients with dilated cardiomyopathy. Circ J, 70:857-63.
12. Janand-Delenne B, Savin B, Habib G, et al. 1999. Silent myocardial ischemia in patients with diabetes: who to screen. Diabetes Care 22:1396-1400.
13. Maeda K, Tsutamoto T, Wada A, et al. 1998. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. Am Heart J, 135:825-32.
14. Margolis JR, Gillum RF, Feinleib M, et al. 1974. Community surveillance for coronary heart disease: the Framingham Cardiovascular Disease Survey. Methods and preliminary results. Am J Epidemiol, 100:425-36.
15. Miller VM, Redfield MM, McConnell JP. 2007. Use of BNP and CRP as biomarkers in assessing cardiovascular disease: diagnosis versus risk. Curr Vasc Pharmacol, 5:15-25.
16. Murcia AM, Hennekens CH, Lamas GA, et al. 2004. Impact of diabetes on mortality in patients with myocardial infarction and left ventricular dysfunction. Arch Intern Med, 164:2273-9.
17. Ndrepepa G, Kastrati A, Braun S, et al. 2006. N-terminal probrain natriuretic peptide and C-reactive protein in stable coronary heart disease. Am J Med, 119:e1-8.
18. Nichols GA, Gullion CM, Koro CE, et al. 2004. The incidence of congestive heart failure in type 2 diabetes: an update. Diabetes Care, 27:1879-84.
19. Ogawa K, Oida A, Sugimura H, et al. 2002. Clinical significance of blood brain natriuretic peptide level measurement in the detection of heart disease in untreated outpatients: comparison of electrocardiography, chest radiography and echocardiography. Circ J, 66:122-6.
20. Ogawa S, Takeuchi K, Ito S. 2003. Plasma BNP levels in the treatment of type 2 diabetes with pioglitazone. J Clin Endocrinol Metab, 88:3393-6.
21. Poirier P, Bogaty P, Garneau C, et al. 2001. Diastolic dysfunction in normotensive men with well-controlled type 2 diabetes: importance of maneuvers in echocardiographic screening for preclinical diabetic cardiomyopathy. Diabetes Care, 24:5-10.
22. Ridker PM, Cannon CP, Morrow D, et al. 2005. C-reactive protein levels and outcomes after statin therapy. N Engl J Med, 352:20-8.
23. Ridker PM, Hennekens CH, Buring JE, et al. 2000. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med, 342:836-43.
24. Schulze MB, Rimm EB, Li T, et al. 2004. C-reactive protein and incident cardiovascular events among men with diabetes. Diabetes Care, 27:889-94.
25. Shah SJ, Marcus GM, Gerber IL, et al. 2006. High-sensitivity C-reactive protein and parameters of left ventricular dysfunction. J Card Fail, 12:61-5.
26. Sprafka JM, Burke GL, Folsom AR, et al. 1991. Trends in prevalence of diabetes mellitus in patients with myocardial infarction and effect of diabetes on survival. The Minnesota Heart Survey. Diabetes Care, 14:537-43.
27. Struthers AD, Morris AD. 2002. Screening for and treating left-ventricular abnormalities in diabetes mellitus: a new way of reducing cardiac death. Lancet, 359:1430-2.
28. Tsutamoto T, Wada A, Maeda K, et al. 1997. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation, 96:509-16.
29. UK Prospective Diabetes Study Group. 1998. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet, 352:837-53.
30. Wakugawa Y, Kiyohara Y, Tanizaki Y, et al. 2006. C-reactive protein and risk of first-ever ischemic and hemorrhagic stroke in a general Japanese population: the Hisayama Study. Stroke, 37:27-32.
31. Wang TJ, Larson MG, Levy D, et al. 2004. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med, 350:655-63.
32. Wei M, Gibbons LW, Kampert JB, et al. 2000. Low cardiorespiratory fitness and physical inactivity as predictors of mortality in men with type 2 diabetes. Ann Intern Med, 132:605-11.
33. Wilcox R, Bousser MG, Betteridge DJ, et al. 2007. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macrovascular Events 04). Stroke, 38:865-73.
34. Yoshimura T, Suzuki E, Egawa K, et al. 2006. Low blood flow estimates in lower-leg arteries predict cardiovascular events in Japanese patients with type 2 diabetes with normal ankle-brachial indexes. Diabetes Care, 29:1884-90.
35. Yoshimura M, Yasue H, Okumura K, et al. 1993. Different secretion patterns of atrial natriuretic peptide and brain natriuretic peptide in patients with congestive heart failure. Circulation, 87:464-9.
36. Zuliani G, Volpato S, Blè A, et al. 2007. High interleukin-6 plasma levels are associated with low HDL-C levels in community-dwelling older adults: the InChianti study. Atherosclerosis, 192: 384-90.